Tilray's Record FY2026 Sales Overshadowed by Dilution and Thin U.S. Upside

What happened

Tilray reported record fiscal 2026 revenue, but the market reaction was muted because the headline number masks ongoing dilution and absence of near-term U.S. regulatory catalysts. The company continues to issue shares to fund operations and acquisitions, which dilutes existing holders; the latest 10-Q shows outstanding shares have risen sharply over time, and management has relied on ATM equity. Furthermore, the U.S. hemp-derived THC ban (0.4 mg cap effective November 2026) threatens a key growth product, while federal rescheduling remains uncertain and not fully reflected in the stock. Beverage segment gross margin fell to 31% in Q2 FY2026 from 40% a year earlier, signaling deteriorating profitability in the diversification away from cannabis. Investors are therefore unwilling to assign a premium to top-line growth when underlying cash generation remains weak and policy catalysts are unclear.

Implication

The record revenue does not change the structural overhang of share-count expansion; until management curbs ATM issuance and shows positive free cash flow, any fundamental value is diluted. The U.S. hemp-THC ban remains a material risk with no viable offset currently, so the beverage platform's optionality is worth less than bulls assume. International cannabis growth is the most credible driver, but its contribution is not yet sufficient to offset Canadian price compression and craft beer weakness. At current levels, the risk/reward is roughly balanced, with downside to $6 if regulatory enforcement is strict and upside to $14 only in a bull case of rapid EU liberalization. Use the $7 level as an attractive entry for a tactical position, but only with strict position sizing and clear exit triggers.

Thesis delta

The news reinforces existing concerns rather than shifting the thesis materially. Dilution and limited U.S. exposure are already embedded in our wait rating, but the reminder that the market is discounting those factors suggests upside is capped until operational cash flow inflects. No change to base-case implied value of $10 or attractive entry at $7.